Research progress in hirudin fusion protein--review.
- Author:
Chuan-Ling ZHANG
1
;
Ai-Ping YU
;
Ji-De JIN
;
Chu-Tse WU
Author Information
1. Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Anticoagulants;
pharmacology;
Delayed-Action Preparations;
Drug Delivery Systems;
Glucokinase;
biosynthesis;
genetics;
pharmacology;
Hirudins;
biosynthesis;
genetics;
pharmacology;
Humans;
Platelet Aggregation Inhibitors;
pharmacology;
Recombinant Fusion Proteins;
biosynthesis;
genetics;
pharmacology;
Urokinase-Type Plasminogen Activator;
biosynthesis;
genetics;
pharmacology
- From:
Journal of Experimental Hematology
2007;15(1):215-218
- CountryChina
- Language:Chinese
-
Abstract:
Natural hirudin extracted from the secretion of medical leech salivary gland is a single-chain peptide containing 65 aminoacid residues with molecular weight of 7000 D, and exists in three isomers of HV1, HV2 and HV3. Hirudin possesses three disulfide bridges forming the structure of core cyclic peptides, which binds to the catalytic site of thrombin so as to inhibit the catalysis of thrombin. Its c-terminus rich in acidic aminoacid residues possesses hydrophilicity, and is free on the molecular surface, and can bind with fibrin recognition site of hirudin. The minimal segment of 12 - 16 C-terminal acidic residues keeps the minimal activity of anti-thrombosis. Thus, hirudin, as a potent and specific inhibitor of thrombin, can be used to protect from and to treat clinically thrombosis. As it has some disadvantages such as short half-life, bleeding side-effect and mono-function, and so on, hirudin has been fused with some other functional proteins in recent years. The obtained fusion proteins can prolong the half life of hirudin, or relieve it bleeding side effect, or bring new functions, such as thrombolysis, inhibiting the platelet aggregation, targeting specifically. The research progress in hirudin fusion protein was summarized in this review.
